Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Change in Acquisitions & Divestments: 2015-2024

Historic Change in Acquisitions & Divestments for Rocket Pharmaceuticals (RCKT) over the last 8 years, with Dec 2024 value amounting to $383.5 million.

  • Rocket Pharmaceuticals' Change in Acquisitions & Divestments rose 23.21% to $123.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $376.2 million, marking a year-over-year increase of 1.88%. This contributed to the annual value of $383.5 million for FY2024, which is 23.96% up from last year.
  • As of FY2024, Rocket Pharmaceuticals' Change in Acquisitions & Divestments stood at $383.5 million, which was up 23.96% from $309.3 million recorded in FY2023.
  • Rocket Pharmaceuticals' Change in Acquisitions & Divestments' 5-year high stood at $383.5 million during FY2024, with a 5-year trough of $141.8 million in FY2020.
  • Its 3-year average for Change in Acquisitions & Divestments is $321.9 million, with a median of $309.3 million in 2023.
  • Its Change in Acquisitions & Divestments has fluctuated over the past 5 years, first fell by 15.87% in 2020, then spiked by 92.12% in 2021.
  • Rocket Pharmaceuticals' Change in Acquisitions & Divestments (Yearly) stood at $141.8 million in 2020, then spiked by 92.12% to $272.4 million in 2021, then grew by 0.17% to $272.9 million in 2022, then climbed by 13.35% to $309.3 million in 2023, then climbed by 23.96% to $383.5 million in 2024.